Adaptation of the in vitro micronucleus assay for genotoxicity testing using 3D liver models supporting longer-term exposure durations.


Journal

Mutagenesis
ISSN: 1464-3804
Titre abrégé: Mutagenesis
Pays: England
ID NLM: 8707812

Informations de publication

Date de publication:
12 09 2020
Historique:
received: 15 05 2020
accepted: 23 06 2020
pubmed: 12 8 2020
medline: 8 7 2021
entrez: 12 8 2020
Statut: ppublish

Résumé

Following advancements in the field of genotoxicology, it has become widely accepted that 3D models are not only more physiologically relevant but also have the capacity to elucidate more complex biological processes that standard 2D monocultures are unable to. Whilst 3D liver models have been developed to evaluate the short-term genotoxicity of chemicals, the aim of this study was to develop a 3D model that could be used with the regulatory accepted in vitro micronucleus (MN) following low-dose, longer-term (5 days) exposure to engineered nanomaterials (ENMs). A comparison study was carried out between advanced models generated from two commonly used liver cell lines, namely HepaRG and HepG2, in spheroid format. While both spheroid systems displayed good liver functionality and viability over 14 days, the HepaRG spheroids lacked the capacity to actively proliferate and, therefore, were considered unsuitable for use with the MN assay. This study further demonstrated the efficacy of the in vitro 3D HepG2 model to be used for short-term (24 h) exposures to genotoxic chemicals, aflatoxin B1 (AFB1) and methyl-methanesulfonate (MMS). The 3D HepG2 liver spheroids were shown to be more sensitive to DNA damage induced by AFB1 and MMS when compared to the HepG2 2D monoculture. This 3D model was further developed to allow for longer-term (5 day) ENM exposure. Four days after seeding, HepG2 spheroids were exposed to Zinc Oxide ENM (0-2 µg/ml) for 5 days and assessed using both the cytokinesis-block MN (CBMN) version of the MN assay and the mononuclear MN assay. Following a 5-day exposure, differences in MN frequency were observed between the CBMN and mononuclear MN assay, demonstrating that DNA damage induced within the first few cell cycles is distributed across the mononucleated cell population. Together, this study demonstrates the necessity to adapt the MN assay accordingly, to allow for the accurate assessment of genotoxicity following longer-term, low-dose ENM exposure.

Identifiants

pubmed: 32780103
pii: 5891021
doi: 10.1093/mutage/geaa018
pmc: PMC7486679
doi:

Substances chimiques

Mutagens 0
Aflatoxin B1 9N2N2Y55MH
Methyl Methanesulfonate AT5C31J09G

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

319-330

Subventions

Organisme : Medical Research Council
ID : G1000821
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society.

Références

Part Fibre Toxicol. 2016 Sep 09;13(1):50
pubmed: 27613375
Methods Mol Biol. 2011;740:7-12
pubmed: 21468962
Mutagenesis. 2014 May;29(3):165-75
pubmed: 24675152
Cell. 2007 Aug 24;130(4):601-10
pubmed: 17719539
Nat Protoc. 2009;4(3):309-24
pubmed: 19214182
Toxicol Sci. 2014 Apr;138(2):300-9
pubmed: 24431211
Mutagenesis. 2009 Jul;24(4):285-93
pubmed: 19351890
Biotechnol Adv. 2014 Mar-Apr;32(2):504-13
pubmed: 24440487
Exp Cell Res. 2015 Nov 15;339(1):35-43
pubmed: 26475730
Mutagenesis. 2012 May;27(3):295-304
pubmed: 22058015
Drug Metab Pharmacokinet. 2014;29(3):237-43
pubmed: 24334537
Chem Res Toxicol. 2016 Dec 19;29(12):1936-1955
pubmed: 27661221
Mutat Res. 2020 Feb - Mar;850-851:503135
pubmed: 32247552
Mutat Res. 2012 Jun 14;745(1-2):104-11
pubmed: 21971291
Arch Toxicol. 2019 Apr;93(4):1021-1037
pubmed: 30915487
Food Chem Toxicol. 2017 Aug;106(Pt B):600-608
pubmed: 27554597
Mutat Res. 2003 Jan 10;534(1-2):65-75
pubmed: 12504755
Mutat Res. 2006 Sep 5;607(2):192-204
pubmed: 16781186
Arch Toxicol. 2019 Nov;93(11):3321-3333
pubmed: 31542801
Mutagenesis. 2017 Jan;32(1):233-241
pubmed: 27815329
Methods Mol Biol. 2013;1044:269-89
pubmed: 23896882
Mutat Res Genet Toxicol Environ Mutagen. 2018 Oct;834:35-41
pubmed: 30173862
J Vis Exp. 2020 Jun 5;(160):
pubmed: 32568251
Part Fibre Toxicol. 2014 Oct 20;11:56
pubmed: 25326698
Mutat Res Genet Toxicol Environ Mutagen. 2016 Jul;805:25-37
pubmed: 27402480
Toxicol Sci. 2018 Apr 1;162(2):655-666
pubmed: 29329425
Sci Rep. 2016 May 04;6:25187
pubmed: 27143246
PLoS One. 2019 Jan 24;14(1):e0211078
pubmed: 30677075
Sci Rep. 2019 Jul 22;9(1):10548
pubmed: 31332230
Toxicol Sci. 2018 Aug 1;164(2):391-416
pubmed: 29701824

Auteurs

Gillian E Conway (GE)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Singleton Park Campus, Swansea, Wales, UK.

Ume-Kulsoom Shah (UK)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Singleton Park Campus, Swansea, Wales, UK.

Samantha Llewellyn (S)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Singleton Park Campus, Swansea, Wales, UK.

Tereza Cervena (T)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Singleton Park Campus, Swansea, Wales, UK.
Department of Nanotoxicology and Molecular Epidemiology, Institute of Experimental Medicine of the CAS, Prague, Czech Republic.

Stephen J Evans (SJ)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Singleton Park Campus, Swansea, Wales, UK.

Abdullah S Al Ali (AS)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Singleton Park Campus, Swansea, Wales, UK.

Gareth J Jenkins (GJ)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Singleton Park Campus, Swansea, Wales, UK.

Martin J D Clift (MJD)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Singleton Park Campus, Swansea, Wales, UK.

Shareen H Doak (SH)

In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Singleton Park Campus, Swansea, Wales, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH